NPs loaded with zoledronic acid as an advanced tool for cancer therapy

Zoledronic acid (ZA) has been shown to be beneficial against cancer both directly and indirectly. However, because of its fast absorption by bone, its use in extraskeletal malignancies has been limited. Due to its quick blood clearance, ZA is less effective as a cancer treatment. To utilize the numerous therapeutic properties of ZA, novel delivery strategies are necessary. While maintaining its pharmacological properties, nanomedicine is an excellent method of increasing ZA's circulatory half-life and intratumor accumulation. Nanoparticles (NPs) can enhance drug accumulation in neoplastic tissues by utilizing the increased permeability and retention effect (EPR) of fenestrations in tumor arteries. Loading the molecules inside the NP increases the solubility and stability of the drug and inhibits breakdown by serum proteins. Additionally, the release of the drug could be controlled, preventing early leakage.